Rectal Neoplasms
Conditions
Brief summary
The purpose of this study is to compare the efficacy, prognosis, health economics of different treatment modalities of mid-low rectal cancer in different centers in China, and to conduct cost utility analysis (CUA) on the treatment process of rectal cancer to explore the best treatment modality that meets the actual need of medical units in each region and at each level. The investigators hope to provide evidence-based medical suggestions for medical quality control of rectal cancer and revision of clinical guidelines, and provides a source of decision making for medical management and medical insurance.
Interventions
OTHERRegistry study, no specific intervention
Registry study, no specific intervention
Sponsors
Peking Union Medical College Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* pathologically confirmed rectal adenocarcinoma * located within 12cm below the anal verge
Exclusion criteria
* diagnosed with distant metastasis * multiple primary colorectal cancers * history of previous malignant tumors * Pregnant or lactating women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 3-year OS | 3 years | 3-year overall survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 3-year LR | 3 years | 3-year local recurrence rate |
| 3-year distant metastasis rate | 3 years | 3-year distant metastasis rate |
| neoadjuvant therapy rate | at the time point of surgery of the primary lesion | the percentage of patients who underwent standard neoadjuvant therapy |
| adjuvant therapy rate | at the time point of 3-year follow up | the percentage of patients who underwent standard adjuvant therapy |
| 3-year DFS | 3 years | 3-year disease-free survival |
| R0 resection rate | at the time point of surgery of the primary lesion | the percentage of patients who underwent R0 resection |
| CCR | immediately after the completion of neoadjuvant therapy assessment | Clinical Complete Response |
| pCR | immediately after the completion of surgery | Pathologic Complete Response |
| 30-day mortality | 30 days after the surgery | death occurring within 30 days of the surgery |
| EUS/MRI assessment rate | at the time point of surgery of the primary lesion | the percentage of patients who underwent standard rectal EUS/MRI assessment |
Countries
China
Contacts
Primary ContactYi Xiao, Professor
Outcome results
None listed